Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells
Open Access
- 15 May 2015
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (17), 15321-15331
- https://doi.org/10.18632/oncotarget.4148
Abstract
Recent epidemiological studies showed that metformin, a widely used anti-diabetic drug might prevent certain cancers. Metformin also has an anti-proliferative effect in preclinical studies of both hematologic malignancies as well as solid cancers and clinical studies testing metformin as an anti-cancer drug are in progress. However, all cancer types do not respond to metformin with the same effectiveness or acquire resistance. To understand the mechanism of acquired resistance and possibly its mechanism of action as an anti-proliferative agent, we developed metformin resistant LNCaP prostate cancer cells. Metformin resistant LNCaP cells had an increased proliferation rate, increased migration and invasion ability as compared to the parental cells, and expressed markers of epithelial-mesenchymal transition (EMT). A detailed gene expression microarray comparing the resistant cells to the wild type cells revealed that Edil2, Ereg, Axl, Anax2, CD44 and Anax3 were the top up-regulated genes and calbindin 2 and TPTE (transmembrane phosphatase with tensin homology) and IGF1R were down regulated. We focused on Axl, a receptor tyrosine kinase that has been shown to be up regulated in several drug resistance cancers. Here, we show that the metformin resistant cell line as well as castrate resistant cell lines that over express Axl were more resistant to metformin, as well as to taxotere compared to androgen sensitive LNCaP and CWR22 cells that do not overexpress Axl. Forced overexpression of Axl in LNCaP cells decreased metformin and taxotere sensitivity and knockdown of Axl in resistant cells increased sensitivity to these drugs. Inhibition of Axl activity by R428, a small molecule Axl kinase inhibitor, sensitized metformin resistant cells that overexpressed Axl to metformin. Inhibitors of Axl may enhance tumor responses to metformin and other chemotherapy in cancers that over express Axl.Keywords
This publication has 41 references indexed in Scilit:
- Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancerBMC Cancer, 2013
- Metformin Use and All-Cause and Prostate Cancer–Specific Mortality Among Men With DiabetesJournal of Clinical Oncology, 2013
- AXL and acquired resistance to EGFR inhibitorsNature Genetics, 2012
- Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase AxlGenes & Cancer, 2012
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancerNature Genetics, 2012
- Axl-dependent signalling: a clinical updateClinical Science, 2011
- VimentinSmall GTPases, 2011
- Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy stateJCI Insight, 2010
- Metformin Associated With Lower Cancer Mortality in Type 2 DiabetesDiabetes Care, 2009
- Downregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancerJournal of Biomedical Science, 2008